Cara Therapeutics ( CARA ) announced that it had achieved positive phase 3 results from its phase 3 KALM-1 study treating hemodialysis patients with CKD associated pruritus using KORSUVA injection. There is another catalyst due in the 2nd half of 2019, which are results from an identical lat…